5 completed, 2 unknown, 1 not yet recruiting. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Unknown 2, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Unknown 1 |
Follow Psychomotor Agitation: new trials by email Literature Review of Psychomotor Agitation trials Research Report on Psychomotor Agitation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care Dexmedetomidine Hydrochloride - Hyperactive Delirium, Delirium of Mixed Origin | Phase 1 / Phase 2 | Unknown | Bruyère Health Research Institute. | 50 | 2024-01-30 | 2025-04-15 |
| Memesto Wearable Device for Persons With Dementia Memesto - Alzheimer Disease | Phase 1 | Completed | Edgewater Safety Systems, Inc. | 9 | 2022-08-31 | 2024-01-03 |
| Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal Dexmedetomidine, Placebo - Opioid Withdrawal | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 225 | 2020-06-09 | 2026-08-11 |
| Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia Sublingual film containing Dexmedetomidine, Sublingual Placebo Film - Agitation,Psychomotor, Dementia | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 100 | 2019-12-27 | 2026-08-11 |
| Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film - Agitation, Schizophrenia | Phase 1 | Completed | BioXcel Therapeutics Inc | 135 | 2019-05-22 | 2026-08-11 |
| Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101 Zyprexa IM, Zydis, INP105 - Acute Agitation | Phase 1 | Completed | Impel Pharmaceuticals | 38 | 2018-08-05 | 2018-10-04 |
| Study of Depakote for Behavioral and Psychological Symptoms in Dementia Depakote - Dementia | Phase 1 | Unknown | Hearthstone Alzheimer Care | 20 | 2004-03-01 | 2006-08-15 |
Dementia (3) · Schizophrenia (2) · Alzheimer Disease (1) · Attention Deficit Disorder with Hyperactivity (1) · Behavior (1) · Behavioral Symptoms (1) · Death (1) · Delirium (1) · Morphine Dependence (1) · Opioid-Related Disorders (1) · Parasomnias (1) · Restless Legs Syndrome (1)
Aberrant Motor Behavior in Dementia (8) · Dyskinesias (8) · Mental Disorders (8) · Nervous System Diseases (8) · Neurobehavioral Manifestations (8) · Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Psychomotor Disorders (8) · Signs and Symptoms (8) · Behavior (7) · Behavioral Symptoms (7) · Neurocognitive Disorders (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Schizophrenia Spectrum and Other Psychotic Disorders (2)
Dexmedetomidine (3) · Olanzapine (1) · Valproic Acid (1) · ferrous sulfate (1)
BioXcel Therapeutics Inc (3) · Bruyère Health Research Institute. (1) · Edgewater Safety Systems, Inc. (1) · Hearthstone Alzheimer Care (1) · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1) · Impel Pharmaceuticals (1)
United States (6) · Australia (1) · Canada (1)
BioXcel MM, MD (3) · Alison E Pritchard, PhD (1) · James Downar, MDCM, MSc (1) · Jeffery T. Banker, MS (1) · Mark Vanelli, MD (1) · Niquita Tugiono, MD (1) · Stephen B Shrewsbury, MD (1)